{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"39"}]}],"title":"≤ Day 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"}]}],"title":"Day 13 to Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"≥ Day 22"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"49"}],"units":"transplants"}],"description":"Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"id":"OG002","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Participants who received a transplant. Two participants in the MM group received a second transplant.","reportingStatus":"POSTED","timeFrame":"2 months","title":"Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant","type":"SECONDARY","typeUnitsAnalyzed":"transplants","unitOfMeasure":"number of transplants"}